Vivus wraps up $22M sales of Muse unit

Mountain View-based Vivus Inc. finished selling Muse, its erectile dysfunction drug, for $22 million in cash.
Vivus (NASDAQ: VVUS) could get $1.5 million more from the buyer, Sweden’s Meda A.B., depending on how well Muse does on the market.